AGTC Applied Genetic Technologies Corporation

4.8
-0.03  -1%
Previous Close 4.83
Open 4.81
Price To Book 1.46
Market Cap 123,674,981
Shares 25,765,621
Volume 200,525
Short Ratio
Av. Daily Volume 223,109
Stock charts supplied by TradingView

NewsSee all news

  1. AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)

     -  Administration of AGTC's proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP,

  2. AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020

    - Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date -

  3. Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

    SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the

  4. AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  5. AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia

    Enrollment ongoing in pediatric dose groups Interim data of all adult dose groups expected in 2H of 2020 GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 interim data due 2H 2020.
AAV Gene Therapy
Achromatopsia
Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2 further data due 2H 2020.
AGTC-501
X-linked Retinitis Pigmentosa (XLRP)

Latest News

  1. AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)

     -  Administration of AGTC's proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP,

  2. AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020

    - Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date -

  3. Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

    SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the

  4. AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  5. AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia

    Enrollment ongoing in pediatric dose groups Interim data of all adult dose groups expected in 2H of 2020 GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies

  6. AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  7. AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  8. AGTC Announces Proposed Public Offering of Common Stock

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  9. Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

    SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from

  10. Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

    SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at

  11. AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia

    –Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will include pediatric

  12. AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  13. AGTC Announces Agenda for R&D Day on January 28, 2020 in New York

    Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE)

  14. AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa

    - Data suggest durable and meaningfully improvements in central visual sensitivity- Secondary data showed encouraging improvements in Best Corrected Visual Acuity- All patients dosed continue to demonstrate a favorable

  15. AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  16. AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  17. AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019

    Company to host R&D Day on January 28, 2020, in New York GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company

  18. AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  19. AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies

    -Data support safety and potential clinical utility of AGTC's ocular gene therapy candidates regardless of patients' AAV antibody status- GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) --

  20. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  21. AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019

    Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month XLRP dose expansion data demonstrates

  22. Applied Genetic Technologies Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Applied Genetic Technologies Corp. (NASDAQ:AGTC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September 26, 2019 at 4:30

  23. AGTC to Present at Upcoming Conferences

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  24. AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus

  25. AGTC to Present at Upcoming Conferences

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus